1092682-58-0

Basic information

• Product Name: (E)-3-(4-chlorophenyl)-1-((3aR,6S,7aS)-8,8-dimethyl-2,2-dioxidohexahydro-1H-3a,6-methanobenzo[c]isothiazol-1-yl)prop-2-en-1-one
• Synonyms: (E)-3-(4-chlorophenyl)-1-((3aR,6S,7aS)-8,8-dimethyl-2,2-dioxidohexahydro-1H-3a,6-methanobenzo[c]isothiazol-1-yl)prop-2-en-1-one
• CAS NO: 1092682-58-0
• Molecular Weight: 379.908
• Mol File: 1092682-58-0.mol

Chemical Properties

• CAS DataBase Reference: (E)-3-(4-chlorophenyl)-1-((3aR,6S,7aS)-8,8-dimethyl-2,2-dioxidohexahydro-1H-3a,6-methanobenzo[c]isothiazol-1-yl)prop-2-en-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-3-(4-chlorophenyl)-1-((3aR,6S,7aS)-8,8-dimethyl-2,2-dioxidohexahydro-1H-3a,6-methanobenzo[c]isothiazol-1-yl)prop-2-en-1-one(1092682-58-0)
• EPA Substance Registry System: (E)-3-(4-chlorophenyl)-1-((3aR,6S,7aS)-8,8-dimethyl-2,2-dioxidohexahydro-1H-3a,6-methanobenzo[c]isothiazol-1-yl)prop-2-en-1-one(1092682-58-0)

Safety Data

• Hazardous Substances Data: 1092682-58-0(Hazardous Substances Data)

Upstream product

• 1615-02-7 3-(4-chlorophenyl)prop-2-enoic acid 
• 35086-79-4 cinnamoyl chloride 
• 108448-77-7 (+)-camphorsultam 

Downstream Products

• 142793-24-6 (+)-(1S,2S)-2-(4-chlorophenyl)cyclopropanecarboxylic acid 
• 1612143-65-3 tert-butyl ((1S,2R)-2-(4-chlorophenyl)cyclopropyl)carbamate 
• 1612143-70-0 (1S,2R)-2-(4-chlorophenyl)-N-propylcyclopropan-1-amine 
• 209738-24-9 (1S,2R)-2-(4-chlorophenyl)cyclopropan-1-amine 
• 1612143-75-5 N-(cis-3-(2-(((1S,2R)-2-(4-chlorophenyl)cyclopropyl)(propyl)amino)ethyl)-3-hydroxycyclobutyl)-2-naphthamide 
• 1612143-64-2 ((1S,2S)-2-(4-chlorophenyl)cyclopropyl)((3aR,6S,7aS)-8,8-dimethyl-2,2-dioxidohexahydro-1H-3a,6-methanobenzo[c]isothiazol-1-yl)methanone 
• 393525-60-5 ((1R,2R)-2-(4-chlorophenyl)cyclopropyl)((3aR,6S,7aS)-8,8-dimethyl-2,2-dioxidohexahydro-1H-3a,6-methanobenzo[c]isothiazol-1-yl)methanone 
• 388631-88-7 (+)-(1S,2S)-2-(p-chlorophenyl)cyclopropylmethanol 

Relevant articles and documents

Triazolopyridine ethers as potent, orally active mGlu2positive allosteric modulators for treating schizophrenia

Triazolopyridine ethers with mGlu2positive allosteric modulator (PAM) activity are disclosed. The synthesis, in vitro activity, and metabolic stability data for a series of analogs is provided. The effort resulted in the discovery of a potent, selective, and brain penetrant lead molecule BMT-133218 ((+)-7m). After oral administration at 10 mg/kg, BMT-133218 demonstrated full reversal of PCP-stimulated locomotor activity and prevented MK-801-induced working memory deficits in separate mouse models. Also, reversal of impairments in executive function were observed in rat set-shifting studies at 3 and 10 mg/kg (p.o.). Extensive plasma protein binding as the result of high lipophilicity likely limited activity at lower doses. Optimized triazolopyridine ethers offer utility as mGlu2PAMs for the treatment of schizophrenia and merit further preclinical investigation.

Tranylcypromine substituted cis -hydroxycyclobutylnaphthamides as potent and selective dopamine D3 receptor antagonists

We report a class of potent and selective dopamine D3 receptor antagonists based upon tranylcypromine. Although tranylcypromine has a low affinity for the rat D3 receptor (Ki = 12.8 μM), our efforts have yielded (1R,2S)-11 (CJ-1882), which has Ki values of 2.7 and 2.8 nM at the rat and human dopamine D3 receptors, respectively, and displays respective selectivities of >10000-fold and 223-fold over the rat and human D2 receptors. Evaluation in a β-arrestin functional assay showed that (1R,2S)-11 is a potent and competitive antagonist at the human D3 receptor.